Publikationen
Peer-reviewed journal articles
Accepted, online first & in print
- Varghese NE, Sabat I, Neumann-Böhme S, Schreyögg J, Stargardt T, Torbica A, van Exel J, Barros PP, Brouwer W (2021)
Risk Communication during COVID-19: A Descriptive Study on Familiarity with, Adherence to and Trust in the WHO Preventive Measures, PLOS ONE (online first)
- Candler T, Neumann-Böhme S, Sabat I, Barros PP, Brouwer W, van Exel J, Schreyögg J, Torbica A, Stargardt T(2021)
Blood donation in times of crisis: early insight into the impact of COVID-19 on blood donors and their motivation to donate across European countries, Vox Sanguinis (online first)
- Böhm A, Schneider U, Aberle J, Stargardt T (2021)
Regimen simplification and medication adherence: Fixed-dose versus loose-dose combination therapy for type 2 diabetes, PLOS ONE (online first)
2021
- Pott C, Stargardt T, Schneider U, Frey S (2021)
Do discontinuities in marginal reimbursement affect inpatient psychiatric care in Germany?, European Journal for Health Economics, 22(1): 101-114, doi: 10.1007/s10198-020-01241-5
- Vadia R, Stargardt T (2021)
Impact of Guidelines on the Diffusion of Medical Technology: A Case Study of Cardiac Resynchronization Therapy in the UK, Applied Health Economics and Health Policy, 19(2): 243-252, doi: 10.1007/s40258-020-00610-8
2020
- Böhm AK, Jensen ML, Sørensen MR, Stargardt T (2020)
Real-World Evidence of User Engagement With Mobile Health for Diabetes Management: Longitudinal Observational Study, JMIR Mhealth Uhealth, 8(11):e22212.doi:10.2196/22212
- Blankart KE, Stargardt T (2020)
The impact of drug quality ratings from health technology assessment on the adoption of new drugs by physicians in Germany, Health Economics, 29(S1): 63-82
- Sabat I, Neumann-Böhme S, Varghese NE, Barros PP, Brouwer W, van Exel J, Schreyögg J, Stargardt T (2020)
United but divided: policy responses and people`s perceptions in the EU during the COVID-19 outbreak, Health Policy, 124(9):909-918
- Baumann M, Stargardt T, Frey S (2020)
Cost-utility of internet-based cognitive behavioral therapy in unipolar depression: A Markow model simulation, Applied Health Economics and Health Policy, 18(4):567-578
- Neumann-Böhme S, Varghese NE, Sabat I, Barros PP, Brouwer W, van Exel J, Schreyögg J, Stargardt T (2020)
Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19, European Journal for Health Economics, 21(7):977-982
- Birkner B, Rech J, Stargardt T (2020)
Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis, Plos one, 15(1):e0226754, doi: 10.1371/journal.pone.0226754
- Chandler T, Hiller J, Peine S, Stargardt T (2020)
Blood donation and donors: insights from a large German teaching hospital, Vox Sanguinis, 115(1):27-35
2019
- Frey S, Stargardt T, Schneider U, Schreyögg J (2019)
The Economic Burden of Cystic Fibrosis in Germany from a Payer Perspective, Pharmacoeconomics, 37(8):1029-1039
- Guhl D, Stargardt T, Blankart KE (2019)
Service Quality and perceived customer value in community pharmacies, Health Services Management Research, 32(1):36-48
2018
- Hofer F, Kauczor HU, Stargardt T (2018)
Cost-utility analysis of a potential lung cancer screening program for a high-risk population in Germany: A modelling approach, Lung cancer, 124():189-198
- Fischer K, Koch T, Kostev K, Stargardt T (2018)
The impact of physician-level drug budgets on prescribing behaviour, European Journal for Health Economics, 19(2):213-222 - Stargardt T, Eckmann C, Bouza E, Rossolini GM, Grossi PA (2018) Attitudes of physicians from 10 European countries on adherence and how teatment modalities in ABSSSI affect adherence: results from a Delphi survey, European Journal of Clinical Microbiology & Infectious Diseases
2017
- Blankart CB, Stargardt T (2017)
Preferred supplier contracts in post-patent prescription drup markets, Health Care Management Science, 20(3):419-432
- Achelrod D, Schreyögg J, Stargardt T (2017)
Health-economic evaluation of home telemonitoring for COPD in Germany: evidence from a large population-based cohort, European Journal of Health Economics, 18(7):869-892
- Lauenroth V, Stargardt T (2017)
Pharmaceutical Pricing in Germany: How is Value Determined within the Scope of AMNOG?, Value in Health, 20(7):927-935
2016
- Hostenkamp G, Fischer KE, Borch-Johnsen K (2016)
Drug safety and the impact of drug warnings: An interrupted time series analysis of diabetes drug prescriptions in Germany and Denmark, Health Policy, 120(12):1404-1411
- Müller D, Gerber-Grote A, Stollenwerk B, Stock S, Auweiler PWP, Frey S, ... Hellmich M (2016)
Reporting health care decision models: a prospective reliability study of a multidimensional evaluation framework.Expert Review of Pharmacoeconomics & Outcomes Research, 16(5):619-627
- Achelrod D, Welte T, Schreyögg J, Stargardt T (2016)
Costs and Outcomes of the German Disease Management Programme (DMP) for Chronic Ostructive Pulmonary Disease (COPD) - A large population-based cohort study, Health Policy, 120(9):1029-39
- Fischer K, Heisser T, Stargardt T (2016)
Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia, Health Policy, 120(10):1115-20
- Hofer F, Achelrod D, Stargardt T (2016)
Cost-Utility Analysis of Telemonitoring Interventions for Patients with Chronic Obstructive Pulmonary Disease (COPD) in Germany, Applied Health Economics and Health Policy, 14(6):691-701
- Fischer K, Stargardt T (2016)
The diffusion of generics after patent expiry in Germany, European Journal of Health Economics, 17(8):1027-40
- Guhl D, Fischer K, Schneider U, Stargadt T (2016)
Dispensing behaviour in pharmacy markets, Health Policy, 120(2):190-7.
- Frey S, Blankart CB, Stargardt T (2016)
Economic burden and quality of life effects of chronic lymphocytic leukemia: A systematic review of the literature, Pharmacoeconomics. 34(5): 479-498.
2015
- Achelrod D, Wenzel U, Frey S (2015)
Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations. American Journal of Hypertension, 28(3), 355-361. http://ajh.oxfordjournals.org/content/28/3/355
2014
- Achelrod D, Blankart C, Linder R, Kodolitsch Y, Stargardt T (2014)
The economic impact of Marfan syndrome: a non-experimental, retrospective, population-based matched cohort study, Orphanet Journal of Rare Diseases; 9:90.
- Fischer KE, Leidl R (2014)
Analysing coverage decision-making opening Pandora´s box? Eur J Health Econ. 2014; 15(9):889-906
- Fischer KE, Stargardt T (2014)
Early Benefit Assessment of Pharmaceuticals in Germany Manufacturer´s expectations versus the Fedreal Joint Committee´s Decision. Med Decis Making. 2014 Nov 1;34(8):1030-47
- Frey S (2014)
The economic burden of schizophrenia in Germany: A population based retrospective cohort study using genetic matching. European Psychiatry, 29(8), 479-489
- Stargardt T, Schreyögg J, Kondofersky I (2014)
Measuring the Relationship between Costs and Outcomes: the Example of Acute Myocardial Infarction in German Hospitals, Health Economics, 23(6):653-69.
- Achelrod D (2014)
Policy expectations and reality of telemedecine - a critical analysis of health care outcomes, costs and acceptance for congestive heart failure. Journal of Telemedecine and Telecare. 2014; 20(4): 192-200
- Achelrod D, Stargardt T (2014)
Cost-Utility Analysis Comparing Heavy-Weight and Light-Weight Mesh in Laparoscopic Surgery for Unilateral Inguinal Hernias. Applied Health Economics and Health Policy. 2014; 12(2):151-163
- Fischer KE, Rogowski WH. (2014)
Funding Decisions for Newborn Screening: A Comparative Review of 22 Decision Processes in Europe. International Journal of Environmental Research and Public Health. 2014;11(5):5403–30.
- Frey S, Linder R, Juckel G, Stargardt T. (2014)
Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia – a Markov model parameterized using administrative data. In: European Journal of Health Economics, 15(2), pp.133-142.
2013
- Haas L, Stargardt T, Schreyögg J, Schlösse R, Danzer G, Klapp B (2013)
The trade-off between costs and quality of care in the treatment of psychosomatic patients with somato form pain disorder, Applied Health Economics and Health Policy, 11(4): 359-368.
- Fischer KE, Stollenwerk B, Rogowski WH (2013)
Link between Process and Appraisal in Coverage Decisions An Analysis with Structural Equation Modeling. Med Decis Making. 2013 Nov 1;33(8):1009–25.
- Fischer KE, Rogowski WH, Leidl R, Stollenwerk B (2013)
Transparency vs. closed-door policy: Do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis. Health Policy. 2013 Oktober;112(3):187–96
- Vandoros S, Stargardt T (2013)
Reforms in the Greek pharmaceutical market during the financial crisis, Health Policy, 109(1): 1-6.
- Fischer K. (2013)
Ansätze zur empirischen Analyse von Entscheidungen über die Erstattungsfähigkeit von Gesundheitstechnologien in industrialisierten Ländern. RPG Recht und Politik im Gesundheitswesen. 2013; 19(3): 67-81
- Blankart R, Koch T, Linder R, Verheyen F, Schreyögg J, Stargardt T (2013)
Cost of illness and economic burden of chronic lymphocytic leukemia, Orphanet Jourmal of Rare Diseases, 8(1):32.
2012
- Haas L, Stargardt T, Schreyögg J, Schlössel R, Hofmann T, Danzer G, Klapp BF (2012)
Introduction of DRG-based reimbursement in inpatient psychosomatics - An examination of cost homogeneity and cost predictors in the treatment of patients with eating disorders, Journal of Psychosomatic Research, 73(5): 383-390.
- Roll K, Stargardt T, Schreyögg J (2012)
Effect of type insurance and income on waiting time for outpatient care, Geneva Papers on Risk and Insurance - Issues and Practice, 37(4): 609-632.
- Frey S, Stargardt T (2012)
Performance of Compliance and Persistence Measures in Predicting Clinical and Economic Outcomes Using Administrative Data from German Sickness Funds, Pharmacotherapy, 32(10): 880–889.
- Schreyögg J, Schultz C, Stargardt T (2012)
Focus on designing health care structures and services for rare diseases, Health Policy, 105(2-3): 107-109.
- Stargardt T, Edel MA, Ebert A, Busse R, Juckel G, Gericke CA (2012)
Effectiveness and cost of atypical versus typical antipsychotic treatment in a nationwide cohort of schizophrenic patients in Germany, Journal of Clinical Psychopharmacology, 32(5): 602-607.
- Haas L, Stargardt T, Schreyögg J (2012)
Cost-effectiveness of open versus laparoscopic appendectomy in the US: a multilevel approach with propensity score matching, European Journal of Health Economics, 13(5): 549-560.
- Fischer KE (2012)
Decision-making in healthcare: a practical application of partial least square path modelling to coverage of newborn screening programmes, BMC Medical Informatics and Decision Making. Aug 2;12(1): 83.
- Fischer KE (2012)
A systematic review of coverage decision-making on health technologies - Evidence from the real world, Health Policy;107(2-3): 218-30.
- Bäumler M, Stargardt T, Schreyögg J, Busse R (2012)
Cost-effectiveness of drug-eluting stents in AMI patients in Germany, Applied Health Economics and Health Policy, 10(4): 235-248.
- Schreyögg J, Stargardt T (2012)
Gesundheitsökonomische Evaluation auf Grundlage von GKV-Routinedaten, Bundesgesundheitsblatt, 55: 668-676.
- Stargardt T, Schreyögg J (2012)
A framework to evaluate the effects of small area variations in healthcare infrastructure on diagnostics and patient outcomes of rare diseases based on administratice data, Health Policy, 105(2-3): 110-118.
- Haas L, Stargardt T, Schreyögg J, Schlösser R, Danzer G, Klapp BF (2012)
Inpatient costs and predictors of costs in the psychosomatic treatment of anorexia nervosa, International Journal of Eating Disorders, 45(2):214-221.
2011
- Fischer KE, Leidl R, Rogowski WH (2011)
A structured tool to analyse coverage decisions: Development and feasibility test in the field of cancer screening and prevention, Health Policy, 101(3): 290-299.
- Fischer KE, Grosse SD, Rogowski WH (2011)
The role of health technology assessment in coverage decisions on newborn screening, International Journal of Technology Assessment in Health Care, 27(4): 313–321.
- Stargardt T (2011)
Modeling pharmaceutical prices in Germany as a function of competition and regulation, Applied Economics, 43(29): 4515-4526.
- Schreyögg J, Stargardt T, Tiemann O (2011)
Costs and quality of hospitals in different health care systems: a multi-level approach with propensity score matching, Health Economics, 20(1): 85-100.
- Blankart R, Stargardt T, Schreyögg J (2011)
Availability of and Access to Orphan Drugs: An International Comparison of Pharmaceutical Treatments for Pulmonary Arterial Hypertension, Fabry Disease, Hereditary Angioedema and Chronic Myeloid Leukaemia, Pharmacoeconomics, 29(1): 63-82.
- Roll K, Stargardt T, Schreyögg J (2011)
Zulassung und Erstattung von Orphan Drugs im internationalen Vergleich, Das Gesundheitswesen; 73(8): 504-514.
- Drummond M, Jönsson B, Rutten F, Stargardt T (2011)
Obtaining value for money from pharmaceuticals: a comparison of reference pricing with health technology assessment, European Journal of Health Economics, 12(3):263-271.
- Stargardt T, Mavrogiorgou P, Gericke CA, Juckel G (2011)
Effectiveness and costs of flupentixol compared to other first and second generation antipsychotics in the treatment of schizophrenia, Psychopharmacology, 216(4): 579-87.
2010
- Schreyöegg J, Stargardt T (2010)
The Trade-Off Between Costs and Outcomes: The Case of Acute Myocardial Infarction, Health Services Research, 45(6):1585-601.
- Stargardt T (2010)
The Impact of Reference Pricing on Switching Behaviour and Healthcare Utilisation: The Case of Statins in Germany, European Journal of Health Economics, 11(3): 267-277.
- Schreyögg J, Weller J, Stargardt T, Herrmann K, Dechow T, Glatting G, Krause BJ, Reske SN, Buck AK (2010)
Cost-effectiveness of Hybrid PET/CT Imaging for Staging Non-Small Cell Lung Cancer, The Journal of Nuclear Medicine, 51 (11):1668-1675.
- Buck AK, Herrmann K, Stargardt T, Dechow T, Krause BJ, Schwaiger M, Schreyögg J (2010)
Economic Evaluation of PET and PET/CT in Oncology Evidence and Methodological Approaches, The Journal of Nuclear Medicine, 51(3):401-412.
2009
- Stargardt T, Gonder-Frederick L, Krobot K, Alexander C (2009)
Fear of Hypoglycaemia: Defining a Minimum Clinically Important Difference, in Health and Quality of Life Outcomes, 7(91).
- Marett L, Stargardt T, Mavros P, Alexander C (2009)
Patient-reported outcomes in a survey of patients treated with oral antihyperglycaemic medications: associations with hypoglycaemia and weight gain, in Diabetes Obesity and Metabolism, 11(12): 1138-1144.
- Stargardt T, Alexander C, Yin D (2009)
Treatment choice and effectiveness of adding sulphonylurea or glitazones to metformin for the treatment of type 2 diabetes mellitus, Diabetes Obesity and Metabolism, 11(5): 491-497.
- Weinbrenner S, Assion H, Stargardt T, Busse R, Juckel G, Gericke C (2009)
Antipsychotic prescription patterns for schizophrenic outpatients in Germany, Pharmacopsychiatry, 42(2): 66-71.
2008
- Stargardt T, Weinbrenner S, Busse R, Juckel G, Gericke C (2008)
Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care: retrospective cohort study, Journal of Mental Health Policy and Economics, 11(2): 89-97.
- Stargardt T (2008)
Health service costs in Europe: cost and reimbursement of primary hip replacement in nine countries, Health Economics, 17(S1): 9-20.
- Schreyögg J, Tiemann O, Stargardt T, Busse R (2008)
Cross-country comparisons of costs: the use of episode-specific transitive purchasing power parities with standardised cost categories, Health Economics, 17(S1): 95-103.
before 2007
- Stargardt T, Schreyögg J, Busse R (2007)
Pricing Behaviour of Pharmacies After Market Deregulation for OTC Drugs: The Case of Germany, Health Policy, 84(1): 30-38.
- Stargardt T, Schreyögg J (2006)
The Impact of Cross-reference Pricing on Pharmaceutical Prices – Manufacturers’ Pricing Strategies and Price Regulation, Applied Health Economics and Health Policy, 5(4): 235-247.
- Schreyögg J, Stargardt T, Tiemann O, Busse R (2006)
Methods to determine reimbursement rates for diagnosis related groups (DRG): a comparison of nine European countries, Health Care Management Science, 9(3):215-224.
- Velasco-Garrido M, Schreyögg J, Stargardt T, Busse R (2006)
Description des paniers de soins de neuf pays de l’Union européenne, Revue française des Affaires socials, 2-3:32-90.
- Stargardt T, Schreyögg J, Busse R (2005)
Arzneimittelfestbeträge: Gruppenbildung, Preisberechnung mittels Regressionsverfahren und Wirkungen, Das Gesundheitswesen, 67(7): 469-478.
- Schreyögg J, Stargardt T, Velasco-Garrido M, Busse R (2005)
Defining the benefit basket in nine European countries: Evidence from EU-HelathBASKET project, European Journal of Health Economics, 6(S1): 2-10.
- Busse R, Stargardt T, Schreyögg J (2005)
Determining the benefit basket of the Statutory Health Insurance scheme in Germany: methodologies and criteria, European Journal of Health Economics, 6(S1): 30-36.
- Farhauer O, Borchardt K, Stargardt T (2004)
Bürgerversicherung – Die Wirkung von Kopfprämien auf den Arbeitsmarkt, Zeitschrift für die gesamte Versicherungswissenschaft, 93(3): 349-372.
Non peer-reviewed publications
Books and book chapters
- Busse R, Schreyögg J, Stargardt T [Hrsg.] (2017)
Management im Gesundheitswesen, 4. Auflage, Springer
- Stargardt T, Vandoros S (2014)
Pharmaceutical Pricing and Reimbursement Regulation in Europe, in: Culyer JA (ed.), Encyclopedia of Health Economics, Vol 3. San Diego: Elsevier, 29-36. - Blankart R, Roll K, Heimeshoff M, Stargardt T, Schreyögg J (2014)
Innovationsbedearf in der Gesundheitswirtschaft im Spiegel der Forschung, in: Bieber D, Geiger M (Hrsg.): Personenbezogene Dienstleistungen im Kontext komplexer Wertschöpfung, Springer, pp. 257-267.
- Stargardt T, Schreyögg J (2012)
Leistungsmanagement in der Arzneimittelindustrie, in: Busse R, Schreyögg J, Stargardt T: Management im Gesundheitswesen, Springer, pp. 128-148.
- Stargardt T, Tiemann O (2012)
Personalmanagement im Gesundheitswesen - Einführung und methodische Grundlagen, in: Busse R, Schreyögg J, Stargardt T: Management im Gesundheitswesen, Springer, pp. 336-338.
- Schreyögg J, Stargardt T (2009)
Leistungsmanagement in der Arzneimittelindustrie, in: Busse R, Schreyögg J, Gericke C: Management im Gesundheitswesen, Springer, pp. 122-140.
- Schreyögg J, Stargardt T (2006)
Leistungsmanagement in der Arzneimittelindustrie, in: Busse R, Schreyögg J, Gericke C: Management im Gesundheitswesen, Springer, pp. 123- 141.
Other publications
- Helms TM, Gulba D, Ahrens I, Schäfer A, Hankowitz J, Kuhlencordt P, Lipp HP, Nikol S, Riess H, Stargardt T, Bramlage P (2017)
Therapie und Sekundärprävention der venösen Thromboembolie - Orale Antikoagulation im Wandel, Deutsche Medizinische Wochenschrift 142:1-8
- Helms TM, Silber S, Schäfer A, Masuhr F, Palm F, Darius H, Schrör K, Bänsch S, Bramlage P, Hankowitz J, Karle CA, Stargardt T, Weil J, Geller JC (2016)
Konsenuspapier: Schlaganfallprophylaxe bei Patienten mit nichtvalvulärem Vorhofflimmern, Herzschrittmachertherapie + Elektrophysiologie, 1-2
- Vandoros S, Stargardt T (2013)
Authors´ response to Health service expenditures and efficiencies in Greece, Health Policy, 111(2): 208-209
- Frey S, Stargardt T (2013)
Budget Impact Analyse der Regulierungsinstrumente "Preismoratorium" und "Kollektivrabatt" anhand der Arzneimittelausgaben für Antipsychotika, Working Paper.
- Schreyögg J, Schultz C, Stargardt T (2012)
Focus on designing health care structures and services for rare diseases, Health Policy, 105(2-3):107-109.
- Roll K, Stargardt T, Schreyögg J (2012)
Einfluss von Versichertenstatus und Einkommen auf die Wartezeit im ambulanten Bereich, Monitor Versorgungsforschung, 5(5):27-29.
- Stargardt T (2006)
Focus on Germany, Reference Pricing, in: Pharmaceutical Marketing Europe, 3(1):32-34.
- Farhauer O, Borchardt K, Stargardt T (2005)
Bürgerversicherung * Systematisierung und Bewertung der Reformvarianten, in: Wirtschaftswissenschaftliches Studium WiSt, 34(6):308-314.
Sortieren nach: